What Oneness Biotech does

Oneness Biotech is a Taiwanese biopharmaceutical company founded in 2008 that develops drug therapies for chronic wounds, with pipeline candidates targeting diabetic foot ulcers, pressure ulcers, and venous leg ulcers. The company is publicly listed on the Taiwan Stock Exchange (ticker: 4743) and operates with a small headcount of 51-100 employees, headquartered in Taipei, Taiwan.

The company's core product development is centered on wound-care therapeutics competing in a market whose United States arm recorded approximately 7 million chronic wound cases in 2023, broken down across pressure ulcers (38%), diabetic foot ulcers (35%), and venous ulcers (18%). Direct competitive context includes Paracrine Inc, MediWound, and PolarityTE per DelveInsight's chronic wound pipeline landscape report. The company's technology focus is on drug candidates for wound healing rather than devices or wound dressings.

The business model appears to be asset-light and partnership-led: a 51-100 employee organization producing multi-billion TWD scale reported revenue is inconsistent with a direct-sales commercial operation and is more consistent with licensing royalties, milestone payments, and partnership-based commercialization of pipeline assets, with revenue lumpiness (e.g., a 2022 outlier of NT$34.66B against ~NT$2.4B-3.6B in surrounding years) further suggesting milestone-driven mechanics. However, the lack of visible product launches, partner logos, or pricing disclosures in the available input limits confirmation of the exact revenue composition. Net income was negative in four of five reported years, indicating the company is still re-investing receipts into R&D and clinical development rather than operating profitably.

Name

Oneness Biotech

Website

https://onenessbio.com.tw

Company type

Private

Founded year

2008

Headcount range

51–100 employees

Short description

Oneness Biotech is a Taiwanese biopharmaceutical company founded in 2008 that develops drug therapies for chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous ulcers. It is listed on the Taiwan Stock Exchange (tpe:4743) and operates with 51-100 employees in Taipei.

Ownership category

akta.pro rank

Product category

Chronic Wound Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Care & Ulcer Management (HLAKACAN), Wound Care & Diabetic Foot Infection (HLAKAGAK)

Keywords

• Drug development
• Chronic wound therapy
• Biopharmaceutical R&D
• Wound care biologics
• Clinical pipeline development

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Oneness Biotech is a drug research and development company advancing pipeline products for the chronic wounds market. Its pipeline targets pressure ulcers, diabetic foot ulcers, and venous ulcers, with candidates in clinical development stages intended to address significant unmet treatment need in chronic wound care.

Differentiator

Problem solved

Functional benefit

Products and services

• Chronic wound therapy pipeline (clinical-stage) Clinical-stage drug candidates being developed by Oneness Biotech to treat chronic wounds, with therapeutic focus on pressure ulcers, diabetic foot ulcers, and venous ulcers; intended for healthcare providers treating chronic wound patients.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Smith+Nephew: Global medical device major with a substantial advanced wound management portfolio. Represents the scaled commercial incumbent that any approved Oneness therapy would eventually compete against.
• Coloplast: Global leader in wound care and ostomy management with established sales channels into hospitals and home care. Comparable target market and customer ecosystem for Oneness.
• Integra LifeSciences: Medical technology company with regenerative tissue technologies and wound-care products. Competes with Oneness at the biologic/regenerative end of the wound-care market.
• Convatec: Large wound-care and ostomy company with a broad portfolio including advanced dressings and skin substitutes. A relevant comparator for the chronic-wound therapeutic category Oneness targets.
• 3M Health Care (Solventum): Major wound-care incumbent with advanced dressings, negative-pressure wound therapy, and skin-health products. Represents the broad commercial competitive set for any approved Oneness therapy.

Direct peers

• PolarityTE: Regenerative medicine company focused on skin and wound healing using autologous cell-based approaches. Comparable to Oneness in therapeutic modality and chronic-wound target market.
• MiMedx: Developer and commercializer of placental tissue allografts for wound care and surgical applications. Competes in the same biologic wound-healing space as Oneness's pipeline.
• Organogenesis: Commercial-stage regenerative medicine company selling skin substitutes (e.g., Apligraf, Dermagraft) for chronic wounds. Comparable biologic/regenerative modality serving the same patient population.
• MediWound: Specialty biotech developing enzymatic and biologic therapies for chronic and burn wounds. Directly comparable to Oneness as a small clinical-stage company named alongside it in chronic-wound market analyses.
• Paracrine: Biotech developing cell- and biologic-based therapies for chronic wounds. Named alongside Oneness as a chronic-wound pipeline competitor in DelveInsight's market report.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oneness Biotech